You are here

Alpha Cognition Inc. 1OCT2023 Warrants

Listing Exchange: 
CSE
Status: 
Delisted
Industry: 
Diversified Industries
Symbol: 
ACOG.WT
CSE Index: 
Currency: 

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

You are here

Alpha Cognition Inc. 1OCT2023 Warrants (ACOG.WT)

SEDAR Information

Company Info

Address
301,1228 Hamilton Street
Vancouver, BC V6B 6L2
Canada
Phone
(604) 564-9244
Email
mmcfadden@alphacognition.com
Website
https://www.alphacognition.com
Listing date
Monday, May 1, 2023

Capitalization

Issued & Outstanding: 
9602500
Reserved for Issuance: 
0

News Releases

Bulletins

03/10/2023

2023-1003 - Expiry - Alpha Cognition Inc. - 1OCT2023 Warrants (ACOG.WT)

le 3 octobre/October 2023

Alpha Cognition Inc. - 1OCT2023 Warrants listed on May 1, 2023 expired on October 1, 2023.

Trading is currently halted.

The warrants will be delisted at market close October 3, 2023.

________________________

Alpha Cognition Inc. - 1OCT2023 Les bons de souscription cotés le 1er mai 2023 ont expiré le 1er octobre 2023.

CSE Filings